EI
RGLS

EAM Investors’s Regulus Therapeutics RGLS Stock Holding History

EAM Investors’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-499
Closed -$961K – 387
2014
Q4 		$961K Buy
+499
New +$888K 0.13% 295
2013
Q4 		– Sell
-1,917
Closed -$2.17M – 348
2013
Q3 		$2.17M Buy
1,917
+698
+57% +$823K 0.43% 62
2013
Q2 		$1.44M Buy
+1,219
New +$1.16M 0.31% 108

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM Investors's RGLS Position: Q1 2015 in Review

EAM Investors sold out of Regulus Therapeutics (RGLS) in Q1 2015, closing a stake of 499 shares — an estimated $961K sold.

EAM Investors first reported a position in RGLS in Q2 2013 and held it in 3 quarters. The position peaked at $2.17M in Q3 2013. 88 funds tracked by Wall St. Rank hold RGLS as of Q1 2015.

  • EAM Investors reported no remaining Regulus Therapeutics position as of Q1 2015 after selling out during the quarter.
  • EAM Investors sold 499 Regulus Therapeutics shares in Q1 2015, an estimated $961K.
  • EAM Investors first reported a position in Regulus Therapeutics in Q2 2013 and held it in 3 quarters.
  • EAM Investors's Regulus Therapeutics position peaked at $2.17M in Q3 2013.
  • 88 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q1 2015.

Based on EAM Investors's 13F filing for Q1 2015, filed 7 May 2015.